Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel

Assessing and Addressing the Risk of Venous Thromboembolism Across the Spectrum of Gender Affirming Care: A Review.

Publication ,  Journal Article
Arrington-Sanders, R; Connell, NT; Coon, D; Dowshen, N; Goldman, AL; Goldstein, Z; Grimstad, F; Javier, NM; Kim, E; Murphy, M; Poteat, T ...
Published in: Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
April 2023

Accumulating evidence demonstrates that gender affirming hormone therapy (GAHT) improves mental health outcomes in transgender persons. Data specific to the risks associated with GAHT for transgender persons continue to emerge, allowing for improvements in understanding, predicting, and mitigating adverse outcomes while informing discussion about desired effects. Of particular concern is the risk of venous thromboembolism (VTE) in the context of both longitudinal GAHT and the perioperative setting. Combining what is known about the risk of VTE in cisgender individuals on hormone therapy (HT) with the evidence for transgender persons receiving HT allows for an informed approach to assess underlying risk and improve care in the transgender community.Hormone formulation, dosing, route, and duration of therapy can impact thromboembolic risk, with transdermal estrogen formulations having the lowest risk. There are no existing risk scores for VTE that consider HT as a possible risk factor. Risk assessment for recurrent VTE and bleeding tendencies using current scores may be helpful when assessing individual risk. Gender affirming surgeries present unique perioperative concerns, and certain procedures include a high likelihood that patients will be on exogenous estrogens at the time of surgery, potentially increasing thromboembolic risk.Withholding GAHT due to potential adverse events may cause negative impacts for individual patients. Providers should be knowledgeable about the management of HT in transgender individuals of all ages, as well as in the perioperative setting, to avoid periods in which transgender individuals are off GAHT. Treatment decisions for both anticoagulation and HT should be individualized and tailored to patients' overall goals and desired outcomes, given that the physical and mental health benefits of gender affirming care may outweigh the risk of VTE.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

DOI

EISSN

1934-2403

ISSN

1530-891X

Publication Date

April 2023

Volume

29

Issue

4

Start / End Page

272 / 278

Related Subject Headings

  • Venous Thromboembolism
  • Transsexualism
  • Transgender Persons
  • Humans
  • Gender Identity
  • Estradiol
  • Endocrinology & Metabolism
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Arrington-Sanders, R., Connell, N. T., Coon, D., Dowshen, N., Goldman, A. L., Goldstein, Z., … Goldstein, R. H. (2023). Assessing and Addressing the Risk of Venous Thromboembolism Across the Spectrum of Gender Affirming Care: A Review. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 29(4), 272–278. https://doi.org/10.1016/j.eprac.2022.12.008
Arrington-Sanders, Renata, Nathan T. Connell, Devin Coon, Nadia Dowshen, Anna L. Goldman, Zil Goldstein, Frances Grimstad, et al. “Assessing and Addressing the Risk of Venous Thromboembolism Across the Spectrum of Gender Affirming Care: A Review.Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 29, no. 4 (April 2023): 272–78. https://doi.org/10.1016/j.eprac.2022.12.008.
Arrington-Sanders R, Connell NT, Coon D, Dowshen N, Goldman AL, Goldstein Z, et al. Assessing and Addressing the Risk of Venous Thromboembolism Across the Spectrum of Gender Affirming Care: A Review. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2023 Apr;29(4):272–8.
Arrington-Sanders, Renata, et al. “Assessing and Addressing the Risk of Venous Thromboembolism Across the Spectrum of Gender Affirming Care: A Review.Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, vol. 29, no. 4, Apr. 2023, pp. 272–78. Epmc, doi:10.1016/j.eprac.2022.12.008.
Arrington-Sanders R, Connell NT, Coon D, Dowshen N, Goldman AL, Goldstein Z, Grimstad F, Javier NM, Kim E, Murphy M, Poteat T, Radix A, Schwartz A, St Amand C, Streed CG, Tangpricha V, Toribio M, Goldstein RH. Assessing and Addressing the Risk of Venous Thromboembolism Across the Spectrum of Gender Affirming Care: A Review. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2023 Apr;29(4):272–278.

Published In

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

DOI

EISSN

1934-2403

ISSN

1530-891X

Publication Date

April 2023

Volume

29

Issue

4

Start / End Page

272 / 278

Related Subject Headings

  • Venous Thromboembolism
  • Transsexualism
  • Transgender Persons
  • Humans
  • Gender Identity
  • Estradiol
  • Endocrinology & Metabolism
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences